Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
28.45
-0.42 (-1.45%)
Nov 20, 2024, 4:00 PM EST - Market closed
Castle Biosciences Employees
Castle Biosciences had 610 employees as of December 31, 2023. The number of employees increased by 67 or 12.34% compared to the previous year.
Employees
610
Change (1Y)
67
Growth (1Y)
12.34%
Revenue / Employee
$511,275
Profits / Employee
$9,959
Market Cap
796.81M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Healthcare Services Group | 33,400 |
AbCellera Biologics | 586 |
Autolus Therapeutics | 471 |
Relay Therapeutics | 323 |
Evolus | 273 |
Pliant Therapeutics | 158 |
Capricor Therapeutics | 102 |
Cullinan Therapeutics | 85 |
CSTL News
- 1 day ago - Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 2 days ago - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
- 13 days ago - Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - Business Wire
- 14 days ago - Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test - Business Wire
- 15 days ago - Use of Castle Biosciences' DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - Business Wire
- 16 days ago - Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Castle Biosciences Reports Third Quarter 2024 Results - Business Wire
- 22 days ago - Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients - Business Wire